Valomaciclovir

Drug Profile

Valomaciclovir

Alternative Names: ABT 606; EPB-348; M 114; MIV-606; RP-606; Valomaciclovir stearate

Latest Information Update: 27 Nov 2012

Price : $50

At a glance

  • Originator Medivir AB
  • Developer Epiphany Biosciences; Medivir AB
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Herpes zoster; Infectious mononucleosis; Multiple sclerosis

Most Recent Events

  • 30 Sep 2012 Discontinued - Preclinical for Multiple sclerosis in USA (PO)
  • 30 Sep 2012 Discontinued - Phase-II for Infectious mononucleosis in USA (PO)
  • 30 Sep 2012 Discontinued - Phase-II for Herpes zoster in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top